7 Results for "

Rett

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Rett" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-105296
CAS No.: 195615-83-9
Purity:  99.51%
Target:  

Sigma Receptor mAChR

Research Areas:  

Cancer

Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
loading...
    loading...
Cat. No.: HY-117727
CAS No.: 146062-44-4
Purity:  99.23%
Synonyms: MIN-102; Hydroxypioglitazone
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-108905
CAS No.: 68562-41-4
Synonyms: Human IGF-I; FK 780
Target:  

IGF-1R

Research Areas:  

Metabolic Disease

Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
loading...
    loading...
Cat. No.: HY-132806
CAS No.: 2230009-48-8
Purity:  99.93%
Synonyms: RG-7816; RO-7017773
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
loading...
    loading...
Cat. No.: HY-110190
CAS No.: 1630936-95-6
Purity:  99.94%
Synonyms: ML396
Target:  

mGluR

Research Areas:  

Neurological Disease

VU0422288 (ML396) is a positive allosteric modulator of group III mGluRs. VU0422288 inhibits mGluRs with EC50s of 125 nM, 146 nM, and 108 nM for mGluR4, mGluR7, and mGluR8, respectively in calcium mobilization assays. VU0422288 reverses deficits in contextual fear memory, social recognition, and apneas in Rett syndrome (RTT) model mice .
loading...
    loading...
Cat. No.: HY-176266
Research Areas:  

Neurological Disease

KIT-13 is an orally active plasmalogen derivative to inhibit neuroinflammation and mitochondrial DNA leakage associated with Mecp2 deficiency. KIT-13 significantly reduce neurological symptoms and improves the life span of the Rett Syndrome (RTT) model mice. KIT-13 can be used for the study of RTT and other neuroinflammation-related diseases.
loading...
    loading...
Cat. No.: HY-105296R
CAS No.: 195615-83-9
Research Areas:  

Cancer

Blarcamesine (Standard) is the analytical standard of Blarcamesine (HY-105296). This product is intended for research and analytical applications. Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
loading...
    loading...